Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Illumina (ILMN)

Illumina appoints Eli Lilly R&D executive Daniel Skovronsky to its board of directors

Neutral Impact 2 of 5 leadership Written later

Illumina expanded its board from nine to ten members on June 16, 2026, and appointed Daniel M. Skovronsky, M.D., Ph.D., effective immediately. Dr. Skovronsky is Chief Scientific and Product Officer of Eli Lilly and Company, and the filing says he qualifies as an independent director under Nasdaq and SEC rules. The filing describes this as a board governance change and does not report any financial results or guidance.

Key points

  • Board size increased from nine to ten members; Dr. Skovronsky appointed effective June 16, 2026
  • Dr. Skovronsky will stand for election at the 2027 annual meeting for a one-year term
  • Filing states he is independent under Nasdaq and SEC rules and has no related-party transactions reportable under Item 404(a)
  • He will participate in the non-employee director compensation programs described in the April 9, 2026 proxy statement

The filing

CompanyIllumina (ILMN)
Form8-K, current report
Filed with the SECJun 23, 2026, 9:08 AM ET
Accession number0001110803-26-000138

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.